Trial Profile
A phase IIb, randomized, parallel group, double-blind, double-dummy, multi-center, multi-national, multi-dose study of DU-176b compared to dalteparin in patients undergoing elective unilateral total hip replacement
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Dalteparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Acronyms STARTS-II
- Sponsors Daiichi Sankyo Inc
- 29 Jun 2010 Results published in Thrombosis and Haemostasis.
- 02 Sep 2008 Results presented at the European Society of Cardiology Congress 2008.
- 30 Aug 2008 Primary endpoint 'Venous thromboembolism event rate' has been met, according to results reported at the Annual Congress of the European Society of Cardiology.